Explain this page
Arphra AIPlain-English read on PTC Inc.’s valuation06-10today
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5d
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5d
- Orbit Makes PTC's Recent Pullback Interesting Despite Execution Risks6d
- PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes7d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$291.51
+158.44% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
9bull4bear
±5% threshold
Analyst PT consensus: $194.80 (+72.70%)
Candlestick · 1Y
Open in chart workstation →PTC
114.75-31.06%H 219.69L 108.50MA50 137.15MA200 166.16Avg vol 1.1M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.87% | -1.43% | -22.45% | -23.40% | -35.60% | -34.13% | -31.28% | -19.04% | -14.78% | +194.38% | +6204.95% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$10.79M
10 txns
Net flow
−$10.79M
Aftermarket
LiveLast trade
$112.80
7 sh
Bid
$114.22
37 sh
Ask
$119.50
300 sh
Spread
$5.280
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Dec 2025 | $685.83M | $166.52M | $1.39 |
| Q4 Sep 2025 | $893.8M | $347.79M | $2.94 |
| Q3 Jun 2025 | $643.94M | $141.33M | $1.17 |
| Q2 Mar 2025 | $636.37M | $162.64M | $1.35 |
| Q1 Dec 2024 | $565.13M | $82.23M | $0.68 |
| Q4 Sep 2024 | $626.55M | $126.52M | $1.04 |
Sector & industry today
LiveSectors
- Real Estate+1.39%
- Technology+1.16%
- Utilities+0.92%
- Communication Services+0.72%
- Energy+0.43%
- Consumer Defensive+0.34%
- Financial Services+0.22%
- Basic Materials+0.16%
- Consumer Cyclical+0.12%
- Healthcare-0.34%
- Industrials-0.52%
Top industries (issuer's industry highlighted)
- Software - Application+0.07%
- Software - Services+5.98%
- Electronic Gaming & Multimedia+4.44%
- Investment - Banking & Investment Services-3.81%
- Medical - Equipment & Services+3.76%
- Travel Services+3.38%
- Communication Equipment+2.94%
- Biotechnology+2.86%
- Independent Power Producers+2.74%
- Manufacturing - Metal Fabrication+2.71%
- Broadcasting+2.54%
- Computer Hardware+2.32%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$194.80
+72.70% upside
Low
$180.00
Median
$195.00
High
$210.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·Jun 17, 2026
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com·Jun 17, 2026
- Orbit Makes PTC's Recent Pullback Interesting Despite Execution Risksseekingalpha.com·Jun 16, 2026
- PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notesprnewswire.com·Jun 15, 2026
- PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notesprnewswire.com·Jun 15, 2026
- PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notesprnewswire.com·Jun 15, 2026
- PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notesprnewswire.com·Jun 15, 2026
- PTC Launches PTC Orbit, an AI-Powered As-Maintained System of Intelligence for Manufacturersprnewswire.com·Jun 11, 2026
Recent analyst activity
DB- Jun 18, 2026GradeNeutralPTC initiated with a Neutral at BNP ParibasExane BNP Paribas
- Jun 18, 2026PT$130.00PTC initiated with a Neutral at BNP ParibasBNP Paribas
Peers
Total assets
$6.62B
Total debt
$1.37B
Cash & equiv
$184.42M
Operating CF
$867.7M
Free cash flow
$856.69M
Buybacks
-$300M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Lathan Corinna director | Sell | 675 | $106.14K | Mar 16, 2026 |
VON STAATS AARON C officer: EVP, Chief Legal Officer | Sell | 2,639 | $422.24K | Mar 03, 2026 |
VON STAATS AARON C officer: EVP, Chief Legal Officer | Sell | 232 | $37.37K | Feb 11, 2026 |
VON STAATS AARON C officer: EVP, Chief Legal Officer | Sell | 8 | $1.3K | Feb 11, 2026 |
Talvitie Kristian officer: EVP, Chief Financial Officer | Sell | 40,061 | $6.93M | Dec 09, 2025 |
Talvitie Kristian officer: EVP, Chief Financial Officer | Sell | 10,230 | $1.78M | Dec 09, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.74B | $982.39M | $734M | $6.08 | +26.80% |
| FY 2024 | $2.3B | $588.06M | $376.33M | $3.12 | +16.37% |
| FY 2023 | $2.1B | $458.47M | $245.54M | $2.06 | +11.71% |
| FY 2022 | $1.93B | $447.36M | $313.08M | $2.65 | +16.19% |
| FY 2021 | $1.81B | $380.75M | $476.92M | $4.03 | +26.39% |